Objective: Endothelin-1 (ET-1) is not only a potent vasoconstrictor but also a stimulator of polymorphonuclear leukocyte (PMN) aggregation and adhesion. The aim of this study was to investigate whether an ET receptor antagonist attenuates the PMN-mediated A contractile dysfunction following myocardial ischaemia. Methods: Isolated rat hearts were perfused according to the Langendorff method. The hearts were subjected to global ischaemia and reperfused with buffer solution only, or human PMNs dissolved in rat plasma (HNRP).
Introduction
receptors located on the endothelium produce vasodilation by releasing nitric oxide or prostacyclin [10] . The potent endothelium-derived vasoconstrictor peptide, Following myocardial ischaemia and reperfusion in endothelin-1 (ET-1) [1] , has been suggested to play an experimental animals, there is an enhanced myocardial important role in cardiovascular diseases [2] . Several production and release of ET [11, 12] , which seems to be clinical studies have shown that circulating plasma levels derived from the jeopardised myocardial area [13] . In of endothelin-like immunoreactivity (ET-LI) are increased addition, the vasoconstrictor response to exogenous ET-1 in patients with advanced atherosclerosis [3] and myocaris enhanced [13, 14] , and the number of ET-1 binding sites dial infarction [4] . Exogenous ET-1 causes marked coris increased following ischaemia / reperfusion. These findonary constriction in several species [5, 6] , which may ings all indicate a pathophysiological role of ET-1 in the result in ischaemic damage [7] . Two different subtypes of development of ischaemia / reperfusion injury. ET receptors, ET and ET , have been characterised and A monoclonal antibody against ET-1 (AwETN40) was A B cloned [8, 9] . ET and ET receptors located on vascular initially used to elucidate the pathophysiological role of A B smooth muscle mediate vasoconstriction, whereas ET endogenous ET-1. The antibody was shown to reduce the B myocardial infarct size in a rat model of ischaemia / re-perfusion in vivo [15] . Moreover, the peptide-based, plasma. During early reperfusion, ET-1 or LU 135252 was specific ET receptor antagonist, BQ 123, and the nonadministered via the perfusion column. To assess contrac-A peptide mixed ET / ET receptor antagonist, bosentan, tile function, a latex balloon connected to a pressure A B reduced infarct size in the dog and pig, respectively transducer (Gould, USA) was inserted into the left ven- [16, 17] . The mechanism underlying the proposed cardiotricular cavity via the left atrium. Left ventricular endprotective effect of ET receptor antagonists remains undiastolic pressure (LVEDP) was set at 5 mmHg by clear.
inflating the balloon with physiological saline. Left venIt has been reported that ET-1 produces marked effects tricular pressure and its electronically differentiated derivaon polymorphonuclear leukocytes (PMNs). Thus, ET-1 tive, dP/dt, were continuously recorded on a polygraph stimulates aggregation of human PMNs [18] , increases (Model 7D, Grass Instruments, USA). Coronary flow was PMN intracellular free calcium mobilisation [19, 20] and measured by collecting the effluent, and heart rate was superoxide anion production by PMNs [21] . ET-1 stimudetermined from the pressure registration every 5 min. lates PMNs to adhere to endothelial cells and to accumulate in the isolated rabbit heart. These effects are blocked 2.2. Neutrophil preparation by an antibody against the integrin complex [22] .
Myocardial ischaemia initiates an acute inflammatory Human buffy coat prepared from citrated whole blood of response in which PMNs are of importance. PMNs may human volunteer donors was supplied by the Karolinska contribute to myocardial damage by releasing oxygenHospital Blood Centre. A 20-ml volume of the buffy coat derived free radicals, proteases and arachidonic acid was carefully layered on the top of 15 ml of low density metabolites [23] . Since ET-1 has been demonstrated to Percoll (55%) and 15 ml of high density Percoll (74%) in stimulate PMNs, it is of interest to evaluate the role of conical plastic tubes (Sarstedt, Numbrecht, Germany). The ET-1 in PMN-induced myocardial ischaemia / reperfusion tubes were centrifuged at 1300 rpm for 25 min at room injury.
temperature. The neutrophil-rich band between the two The aim of the present study was therefore to investigate density gradients was aspirated and dissolved in 50 ml of whether or not a selective non-peptide ET receptor Dulbecco's phosphate-buffered saline without CaCl and A 2 antagonist protects from ischaemia / reperfusion injury in MgCl (D-PBS) and centrifuged at 1400 rpm for 5 min.
2 the isolated rat heart and whether such an effect is related The supernatant was discarded and the pellet was washed to inhibition of PMN-induced injury.
twice with D-PBS and centrifuged as before. The precipitant was exposed to 2 ml of distilled water for 30 s, to lyse contaminating erythrocytes. The process was stopped by 2. Methods administration of D-PBS to a volume of 50 ml. After another centrifugation at 1400 rpm for 5 min, the pellet All of the investigations were approved by the regional was dissolved in 5 ml of Hank's balanced salt solution ethics committee for animal research and conform with the without CaCl and MgSO (HBSS) [24] and the PMNs 2 4 Guide for the care and use of laboratory animals pubwere counted. at 378C. Two side arms connected to a mixing chamber 1. In both protocols, baseline LVEDP, left ventricular just proximal to the heart cannula were used for the developed pressure (LVDP), dP/dt, heart rate and coronary administration of drugs prior to ischaemia, PMNs and flow were recorded after a 30-min equilibration period. Global ischaemia was induced by stopping the buffer (n58), group G received LU 135252 (10 mmol / l; n58) perfusion. During the reperfusion period LVDP, LVEDP, and group H received ET-1 (0.1 nmol / l; n55), as in dP/dt, heart rate and coronary flow were determined every protocol 1. All three groups were perfused with human 6 5 min. PMNs (50310 ) in 5 ml of rat plasma (HNRP) along with In protocol 1 (Fig. 1a) , five groups of hearts (A-E) were Krebs-Henseleit buffer at the onset of reperfusion and subjected to 30 min of ischaemia followed by 30 min of during the following 5 min. The perfusion was then reperfusion. At the start of ischaemia, the hearts in group continued with Krebs-Henseleit buffer alone. An additional A received 3 ml of vehicle (n58), and groups B (n57) group of hearts (group I) was given plasma (n56) without and C (n58) received 3 ml of LU 135252 (1 and 10 PMNs during the first 5 min of reperfusion. During the last mmol / l, respectively). Groups B and C were also given minute of perfusion with PMNs, coronary effluent was LU 135252 (1 and 10 mmol / l, respectively) during the first collected and the PMN concentration was counted sub-5 min of reperfusion. Groups D (n55) and E (n55) were sequently using a light microscope and a Burker chamber. given ET-1 (1 and 10 nmol / l, respectively) during the first Two groups of hearts were studied using a constant flow 5 min of reperfusion. During the following 25 min, the rate. One group received vehicle and the other received LU hearts were reperfused with Krebs-Henseleit buffer.
135252 (10 mmol / l), as had groups F and G. These In protocol 2 (Fig. 1b) , three groups of hearts (groups experiments were performed in order to distinguish the F-H) were subjected to 20 min of ischaemia followed by possible effects of LU 135252 on PMN accumulation from 45 min of reperfusion. Hearts in group F received vehicle its effect on coronary flow. Accordingly, only the recovery 7 of PMNs in the coronary effluent at 5 min of reperfusion is expressed in percent of the number of PMNs (10 was determined in these experiments. cells / min) added to the perfusate during the same time Separate experiments were performed in order to charperiod. acterise the receptor selectivity of LU 135252 in the All values are presented as the mean6SEM. Comisolated rat heart model. These experiments revealed that parison between the groups were made by one-way LU 135252 (10 mmol / l) significantly attenuated the reducanalysis of variance (ANOVA) followed by Tukey's test. tion in coronary flow induced by ET-1 (10 nmol / l) (7764
The significance level, a, was set at 0.05. Correlation vs. 2966% reduction in coronary flow in the absence and coefficients were calculated using Pearson's linear correlapresence of LU 135252, respectively; P,0.01, Manntion. Whitney U-test). The ET receptor agonist, sarafotoxin 6c B (1-100 nmol / l), induced an initial increase followed by a decrease in coronary flow. These effects were not sig-3. Results nificantly affected by LU 135252. Thus, the maximal increase in coronary flow was 1966 vs. 2265% and the 3.1. Reperfusion with buffer alone ( protocol 1) decrease in coronary flow was 3565 vs. 23610% in the absence and presence of LU 135252 (10 mmol / l), respecThere was a tendency towards improved recoveries of tively (n55).
coronary flow, LVDP and RPP in hearts given LU The method of perfusing rat hearts with human PMNs 1352525 compared to vehicle-treated hearts. However, and rat plasma has been validated previously [25] . A there were no significant differences between the groups mixture of human PMNs and rat plasma does not cause (Table 1) . Furthermore, LU 135252 did not affect LVEDP PMN activation or any measurable complement activation.
in comparison with the vehicle-treated hearts (Table 1) . Furthermore, reperfusion with PMNs alone does not alter Administration of ET-1 (10 nmol / l) resulted in a sigpostischaemic myocardial function, whereas PMNs tonificantly lower coronary flow (2965% recovery) at 5 min gether with plasma causes marked myocardial injury.
of reperfusion in comparison with the vehicle group Therefore, PMNs were only given together with plasma in (7468% recovery; P,0.01). At 30 min of reperfusion, the the present protocol. The postischaemic mean recovery of percentage recovery in coronary flow and myocardial PMNs in untreated hearts using the present experimental performance was only slightly and non-significantly lower model is 7.4% (95% CI, 3.5-11.4; n525).
in the groups receiving ET-1 (1 and 10 nmol / l) compared to the vehicle-treated group (Table 1) . However, the 2.5. Materials recovery of coronary flow was significantly higher in the group given LU 135252 (10 mmol / l) than in the group Sodium heparin was obtained from Lovens (Ballerup, given ET-1 (10 nmol / l) ( Table 1 ). Denmark), Dormicum (midazolam) was from HoffmannLaRoche (Basel, Switzerland), Hyponorm (fluanisonum1 3.2. Reperfusion with HNRP or plasma ( protocol 2) fentanylum) was from Janssen (Beerse, Belgium) and ET-1 was from Alexis Corporation (Laufelfingen, Switzerland).
The stability of the model in the presence of PMNs was Percoll, modified Hanks' balanced salts and modified evaluated in hearts that were not subjected to ischaemia. and was kindly supplied by Dr. Manfred Raschack, Knoll Table 2 . There were no significant differences between the (Ludwigshafen, Germany). LU 135252 was dissolved in 1 groups. mol / l NaOH and saline and adjusted with 0.1 mol / l HCl The functional recovery of the HNRP vehicle group (F) to obtain a pH of 7.5.
was generally poor. During the late part of reperfusion, the recovery of LVDP, dP/dt and RPP was 30-35% of the 2.6. Calculation and statistical analysis pre-ischaemic values (Fig. 2) . LVEDP in this group increased continuously, to 9364 mmHg, during ischaemia The recovery of myocardial performance is expressed in and remained high during reperfusion (Fig. 3) . percent of the pre-ischaemic value. Rate pressure product
The recovery of LVDP of the HNRP plus LU 135252 (RPP) was calculated as the heart rate multiplied by the group (G) increased during reperfusion and was 6063% at LVDP. Outflow of PMNs was calculated as the PMN 45 min of reperfusion, compared to 3469% in the HNRP concentration in the coronary effluent multiplied by corvehicle group (Fig. 2a, P,0 .05). The recovery of dP/ dt of onary flow. The resulting outflow rate of PMNs (cells / min) the HNRP plus LU 135252 group increased continuously during reperfusion and was significantly higher than that of Two hearts were given 1 nmol / l ET-1 in combination with the HNRP vehicle group after 30 min of reperfusion (Fig. HNRP during reperfusion. In these hearts, coronary flow 2b).
was reduced to zero within 1 min and there were signs of Heart rate was not significantly different between the PMN adhesion to the wall of the plastic mixing chamber. two groups reperfused with HNRP plus vehicle or LU
In the group reperfused with rat plasma without PMNs 135252. The recovery of RPP in the HNRP plus LU (group I), the functional recovery was significantly better 135252 group was higher at 30 and 40 min of reperfusion than in the HNRP vehicle group (Figs. 2-4) . On the other compared with the HNRP vehicle group (Fig. 2c) . At 45 hand, myocardial performance at the end of reperfusion did min of reperfusion, the RPP of the HNRP vehicle group not differ significantly between the plasma group and the increased by 5%, due to three hearts with tachycardia.
HNRP plus LU 135252 group. LVEDP was 20-30 mmHg higher in the HNRP vehicle group than in the HNRP plus LU 135252 group during the 3.3. Outflow of PMNs reperfusion period (Fig. 3) .
The initial recovery of coronary flow was significantly The percentage recovery of PMNs in the coronary higher in the HNRP plus LU 135252 group than in the effluent was four-times higher in the HNRP plus LU HNRP vehicle group (Fig. 4) . Following this initial 135252 group than in the HNRP vehicle group and was improvement, there were no significant differences be-20-times higher than in the group given ET-1 together with tween the groups, however. HNRP (Fig. 5) . When data from the HNRP vehicle and Myocardial performance during reperfusion of the hearts HNRP plus LU 135252 groups were compiled, significant given ET-1 (0.1 nmol / l) in combination with HNRP correlations were found between the percentage recovery (group H) was extremely poor, and all hearts ceased in cardiac function and the outflow of PMNs in the beating within 14 min of reperfusion and did not recover.
coronary effluent (Fig. 6 ). There was also a significant Values are expressed as the mean6SEM. Abbreviations as in Table 1 . inverse correlation between the LVEDP during reperfusion the first derivative of left ventricular pressure (dP/dt) and (c) the rate pressure product (heart rate multiplied by LVDP) during 45 min of and the outflow of PMNs (Fig. 6 ).
reperfusion following 20 min of ischaemia. The hearts were given human
To explore the possibility that the differences on outflow 5568% in the HNRP plus LU 135252 group (P,0.01; n55, Mann-Whitney U-test), indicating that the higher recovery in hearts given LU 135252 was unrelated to coronary flow.
Discussion
The pathophysiological role of ET in the development of ischaemia / reperfusion injury has been investigated in several studies in vivo as well as in vitro, but is still far from clarified. It has been reported that ET receptor antagonists protect against myocardial ischaemia and reperfusion injury in vivo [17] . Thus, the non-peptide mixed ET / ET receptor antagonist, bosentan, reduced A B infarct size in a pig model of regional ischaemia / reperfusion [17] . In addition, the peptide ET -specific antagonist, A BQ 123, given directly into the left circumflex coronary artery of dogs resulted in a 40% reduction in infarct size [16] . Moreover, another peptide-based ET receptor an-A tagonist, FR 139317, reduced infarct size in the rabbit when given before, but not after, coronary artery occlusion [27] . Other studies in vivo have resulted in no or inconsistent protection by ET receptor antagonists [28, 29] .
A In the present study, the non-peptide ET receptor A antagonist, LU 135252, did not produce any significant cardioprotective effects in the isolated rat heart reperfused with buffer solution. This is in contrast to our observations that LU 135252 reduced infarct size by 60% in a porcine model of regional ischaemia and reperfusion in vivo [30] . perfused isolated heart. Under in vivo conditions, on the outflow in the post-ischaemic heart, supports this view. Ińó ther hand, PMNs are likely to play an important role in agreement with the report by Lopez Farre et al. [22] , there the development of tissue damage during ischaemia and were clear signs of PMN adhesion to the plastic walls of reperfusion [23] . It was therefore of importance to further the perfusion system in the presence of the high dose of investigate the effect of LU 135252 on ischaemia / reperfu-ET-1. The mechanism by which ET-1 may stimulate PMN sion injury in the presence of PMNs during reperfusion. accumulation in the post-ischaemic heart remains to be The administration of LU 135252 to hearts reperfused established. ET-1 has been suggested to cause aggregation with HNRP significantly enhanced the recovery of LVDP, of human PMNs by the production of platelet activating 21 dP/dt and RPP in comparison with the HNRP vehicle factor via a Ca -dependent mechanism [18] . Furthermore, group. Furthermore, the LVEDP was lower in the HNRP ET-1 increases the expression of the adhesion molecule plus LU 135252 group than in the HNRP vehicle group.
CD11b / CD18 on the PMN surface and an anti-CD18 Interestingly, the outflow of PMNs in the coronary effluent antibody blocks the ET-1-mediated PMN adhesion [22] . It was significantly greater in hearts given LU 135252.
has also been shown that ET-1 induces neutrophil adhesion Administration of a low concentration (0.1 nmol / l) of to cardiac myocytes and aortic endothelial cells by increas-ET-1 in combination with HNRP, on the other hand, ing the expression of the intercellular adhesion molecule, impaired the recovery of myocardial function and outflow ICAM-1 [36] . At least on myocytes, this effect is mediated of PMNs. A ten-fold higher dose of ET-1, in combination via the ET receptor and is dependent on activation of A with HNRP, completely stopped coronary perfusion. By protein kinase C. contrast, ET-1 (up to 10 nmol / l) did not significantly Another possible mechanism by which LU 135252 may impair post-ischaemic myocardial function in the absence protect against PMN-induced injury is that endogenous of PMNs. Taken together, these results indicate that ET-1
ET-1 will more selectively activate ET receptors on the B is involved in the accumulation of PMNs in the reperfused endothelium when ET receptors are blocked. This may A myocardium and in the development of myocardial injury increase the release of nitric oxide [10] , which is known to in the presence of PMNs. Inhibition of PMN accumulation limit PMN-induced cardiac dysfunction after myocardial and PMN-induced injury in the post-ischaemic myocarischaemia and reperfusion in the isolated rat heart [37] . dium seems to be an important mechanism of action of LU Moreover, nitric oxide is known to inhibit adhesion of 135252. This assumption is supported by the close correlaPMNs [38] , partially by inhibition of ICAM-1 expression tion between myocardial functional recovery and the [39] . outflow of PMNs during reperfusion. Since LU 135252
In conclusion, the selective ET receptor antagonist LU A also enhanced the outflow of PMNs in hearts perfused at a 135252 protects the myocardium from ischaemia / reperfuconstant flow rate, the inhibition of PMN accumulation sion injury in the presence of PMNs and inhibits the does not seem to be secondary to changes in coronary accumulation of PMNs in the post-ischaemic heart. The flow, but rather to a direct effect on PMN adhesion. results suggest that an important cardioprotective effect is The duration of the ischaemic periods differed in mediated via inhibition of PMN-mediated injury during protocols 1 and 2 due to the aggravated injury in the reperfusion. presence of PMNs [25] . It can not be entirely excluded that this may have influenced the results. However, pilot experiments revealed that 20 min of ischaemia is too short
